Recent Updates
Recently added Catalysts

Anti-CD40 Agonist Monoclonal Antibody CDX-1140

Phase 2

Ovarian Clear Cell Adenocarcinoma | Biologics | Oncology |Celldex Therapeutics, Inc.|Trials Updated: Aug 14, 2026

Anti-CD40 Agonist Monoclonal Antibody CDX-1140 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Feb 2022

Anti-CD40 Agonist Monoclonal Antibody CDX-1140 target and mechanism

ModalityBiologics

Also known as Agonist CD40 Antibody CDX-1140, Anti-CD40 Agonistic Monoclonal Antibody CDX-1140, CDX 1140

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment80

FDA Designations

No designations recorded

Anti-CD40 Agonist Monoclonal Antibody CDX-1140 clinical trials

Anti-CD40 Agonist Monoclonal Antibody CDX-1140 · 1 trial · 15 indications

Phase 2 1
NCT05231122Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerOvarian Clear Cell Adenocarcinoma
RECRUITING80 Analytics
PHASE2RECRUITING
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Ovarian Clear Cell AdenocarcinomaUnlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of adverse events
Up to 2 years

Evaluated according to National Cancer Institute Common Terminology Criteria for adverse events (NCI CTCAE) version (v)5.0. Will be summarized by cohort and grade using frequencies and relative frequencies.

Objective response rate (ORR)
From first day of treatment Up to 6 months.

Will be summarized by cohort (with or without CDX 1140) using frequencies and relative frequencies, with the ORR estimated using 90% confidence intervals obtained by Jeffrey's prior method. The final analysis will be performed on all n=80 (40 in each cohort) evaluable patients; and if the p-value is less than or equal to 0.10, then the triplet regimen will be considered superior with respect to response.

Secondary Endpoints

Progression free survival (PFS)
From first day of treatment until disease progression or date of death from any cause, assessed up to 2 years
Overall survival (OS)
From first day of treatment until disease progression or date of death from any cause, assessed up to 2 years
Disease control rate (DCR)
Up to 2 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm I (pembrolizumab, bevacizumab)ACTIVE_COMPARATORPatients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.
Arm II (pembrolizumab, bevacizumab, CDX-1140)EXPERIMENTALPatients receive pembrolizumab IV over 30 minutes, bevacizumab IV over 30-90 minutes, and CDX-1140 IV over 90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.

Interventions

NameTypeDescription
Anti-CD40 Agonist Monoclonal Antibody CDX-1140BIOLOGICALGiven IV
BevacizumabBIOLOGICALGiven IV
PembrolizumabBIOLOGICALGiven IV
Quality-of-Life AssessmentOTHERAncillary studies
Questionnaire AdministrationOTHERAncillary studies
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Age \>= 18 years of age. * Recurrent serous (low grade or high grade), endometrioid, or clear cell recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. * Participant can be either platinum-sensitive or platinum-resistant, no more than 4 prior lines of tr...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 10, 2026NCT05231122primaryCompletionDate: changed
LOWNov 10, 2026NCT05231122primaryCompletionDate: changed
LOWNov 10, 2026NCT05231122primaryCompletionDate: changed

Frequently asked questions about Anti-CD40 Agonist Monoclonal Antibody CDX-1140

What is CDX-1140?

CDX-1140 is an investigational monoclonal antibody developed by Celldex Therapeutics, Inc. (ticker CLDX). It is an anti-CD40 agonist antibody being studied in oncology, specifically in a Phase 2 trial for ovarian clear cell adenocarcinoma and related ovarian, fallopian tube, and primary peritoneal cancers. It is not yet approved and remains in clinical development.

What is CDX-1140 used for in ovarian clear cell adenocarcinoma?

CDX-1140 is being studied for the treatment of ovarian clear cell adenocarcinoma and other recurrent ovarian, fallopian tube, and primary peritoneal carcinomas. In the Phase 2 trial, it is given in combination with pembrolizumab and bevacizumab, or with pembrolizumab alone, in patients with recurrent ovarian cancer.

What does CDX-1140 target?

CDX-1140 targets CD40, a receptor on antigen-presenting cells. As an agonist anti-CD40 monoclonal antibody, it is designed to activate CD40 signaling and stimulate immune responses against tumor cells. It is being evaluated in combination with pembrolizumab, a PD-1 inhibitor, and bevacizumab, a VEGF inhibitor.

Who is developing CDX-1140?

CDX-1140 is being developed by Celldex Therapeutics, Inc., which trades under the ticker CLDX. Celldex is the sponsor of the Phase 2 clinical trial evaluating the antibody in recurrent ovarian cancer.

What phase is CDX-1140 in?

CDX-1140 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The ongoing Phase 2 study is currently recruiting participants and has an estimated enrollment of 80 patients.

What clinical trial is CDX-1140 in?

CDX-1140 is being evaluated in the Phase 2 trial NCT05231122, titled "Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer." The trial is recruiting, active controlled, randomized, and enrolling 80 female participants aged 18 years and older in the United States.